EDEN RESEARCH PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.4 GBX | 0.00% |
|
-1.12% | -23.48% |
| Jun. 27 | EARNINGS AND TRADING: Fenikso in profit; Tate & Lyle completes sale | AN |
| Jun. 24 | Eden Research flagship biofungicide granted new authorisation in Spain | AN |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 18.65 | 43.74 | 28.91 | 18.09 | 30.67 | 23.47 |
| Enterprise Value (EV) 1 | 18.15 | 43.74 | 25.47 | 18.09 | 30.67 | 19.77 |
| P/E ratio | -16.7 x | -17.4 x | -10.4 x | -8.05 x | -3.73 x | -14.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 9.1 x | - | 23.5 x | 9.9 x | 9.61 x | 4.69 x |
| EV / Revenue | 8.86 x | - | 20.7 x | 9.9 x | 9.61 x | 3.95 x |
| EV / EBITDA | -27.8 x | - | -11.9 x | -9.43 x | -30.5 x | -32.9 x |
| EV / FCF | - | - | - | - | - | -5.49 x |
| FCF Yield | - | - | - | - | - | -18.2% |
| Price to Book | - | - | - | - | - | 1.91 x |
| Nbr of stocks (in thousands) | 207,189 | 380,340 | 380,340 | 380,859 | 533,353 | 533,353 |
| Reference price 2 | 0.0900 | 0.1150 | 0.0760 | 0.0475 | 0.0575 | 0.0440 |
| Announcement Date | 5/7/20 | 6/30/21 | 5/31/22 | 5/5/23 | 5/7/24 | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | 2.048 | - | 1.229 | 1.827 | 3.192 | 5 |
| EBITDA 1 | -0.6516 | - | -2.133 | -1.919 | -1.005 | -0.6 |
| EBIT 1 | -1.358 | - | -3.208 | -2.567 | -1.867 | -1.7 |
| Operating Margin | -66.29% | - | -261.14% | -140.49% | -58.48% | -34% |
| Earnings before Tax (EBT) 1 | -1.479 | - | -3.396 | -2.568 | -6.92 | -1.7 |
| Net income 1 | -1.145 | -2.27 | -2.789 | -2.237 | -6.494 | -1.5 |
| Net margin | -55.89% | - | -227.01% | -122.44% | -203.45% | -30% |
| EPS 2 | -0.005400 | -0.006600 | -0.007300 | -0.005900 | -0.0154 | -0.003000 |
| Free Cash Flow 1 | - | - | - | - | - | -3.6 |
| FCF margin | - | - | - | - | - | -72% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/7/20 | 6/30/21 | 5/31/22 | 5/5/23 | 5/7/24 | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | -5.887 |
| Net margin | - |
| EPS 2 | -0.0154 |
| Dividend per Share | - |
| Announcement Date | 9/29/23 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 0.5 | - | 3.43 | - | - | 3.7 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | - | -3.6 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | -11.8% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | - | - | 0.0200 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | 0.84 | - | 1.73 | - | - | 4.2 |
| Capex / Sales | 40.81% | - | 140.5% | - | - | 84% |
| Announcement Date | 5/7/20 | 6/30/21 | 5/31/22 | 5/5/23 | 5/7/24 | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.48% | 30.06M | |
| +9.43% | 36.55B | |
| -.--% | 11.62B | |
| +26.24% | 7.88B | |
| +7.90% | 6.88B | |
| -12.58% | 6.88B | |
| -9.24% | 5.64B | |
| -10.25% | 5.37B | |
| -2.57% | 5.15B | |
| +27.31% | 5.01B |
- Stock Market
- Equities
- EDEN Stock
- Financials Eden Research plc
